The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)

Sponsor
University Hospital Dubrava
Study ID
NCT06960629
Status
Enrolling By Invitation

Conditions

  • Glaucoma
  • Pseudophakic Bullous Keratopathy

Eligibility Criteria

Sex
ALL
Age
40 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution — DRUG
    Patients with pseudophakic bullous keratopthy and glaucoma will receive topical netarsudil/latanoprost 1x daily for 3 months.
  • Placebo — DRUG
    Patients with pseudophakic bullous keratopathy and glaucoma will receive topical placebo 8artificial tear substitute) 1x daily for 3 months.

Study Details

The goal of this clinical trial is to learn if topical netarsudil/latanoprost works to treat pseudophakic bullous keratopathy in patients with glaucoma. The main questions it aims to answer are: Does topical netarsudil/latanoprost improves visual function in patients with glaucoma and pseudophakic bullous keratopathy? Does topical netarsudil/latanoprost affects the central corneal thickness (CCT) in patients with glaucoma and pseudophakic bullous keratopathy? Researchers will compare topical netarsudil/latanoprost to a placebo (a look-alike substance that contains no drug) to see if topical netarsudil/latanoprost works to treat pseudophakic bullous keratopathy (PBK). Participants will take topical netarsudil/latanoprost or a placebo every day for 3 months and visit the clinic once every two weeks for checkups and tests.

Key Dates

Start date
Apr 1, 2025
Status verified
May 2025
Primary completion
Apr 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Rock inhibitor group
    Group 1 or ROCK inhibitor group will receive topical netarsudil/latanoprost 1x daily for 3 months.
  • Arm: Placebo group
    Placebo group will receive topical placebo (artificial tear substitute) 1x daily for 3 months.

Primary Outcome Measure

Visual acuity (VA) [ Time Frame: 3 months ]

Related Studies